AP - Researchers have for the first time developed a "risk score" in an attempt to predict future cases of dementia. In a study published Thursday in the publication Lancet Neurology, researchers identified several key factors that are believed to determine dementia in later life.

Reuters - As with heart disease and other illnesses, lifestyle factors are key to preventing the risk of Alzheimer's disease and other forms of dementia, Swedish researchers said on Thursday.

U.S scientists said that with a simple eye test, early dementia can be determined. The test makes use of a non-invasive laser to inspect the lens of the eye.

Reuters - Diabetes and pre-diabetic conditions appear to worsen the risk of Alzheimer's disease but drugs that help regulate blood sugar may help patients with dementia as well, researchers report.

HealthDay - MONDAY, July 17 (HealthDay News) -- Gradual weight loss can precede dementia and begin as early as 10 years prior to memory loss, concludes a Mayo Clinic study involving women with and without dementia.

A study conducted by team of Mayo Clinic doctors and released last week shows that weight loss could be a signal that a woman would develop dementia later in life. The study, which analyzed 1,000 people, showed that women who later developed dementia had a drop in weight even 10 years before they...

HealthDay - SUNDAY, July 16 (HealthDay News) -- The estimated total worldwide cost of caring for people with Alzheimer's disease and dementia now tops $248 billion U.S annually, researchers said Sunday.

HealthDay - SUNDAY, July 16 (HealthDay News) -- The estimated total worldwide cost of caring for people with Alzheimer's disease and dementia now tops $248 billion U.S annually, researchers said Sunday.

Reuters - Depression triples the likelihood that a nursing home resident with dementia will be physically aggressive, a new study shows.

The longest study to date performed to determine if folate and B vitamins can prevent dementia showed there is no benefit to taking a supplement. In the New Zealand study, the homosysteine levels of those taking the supplements - which contained 1,000 micrograms of folate, 500 micrograms of B-12...

The Food and Drug Administration approves Exelon (rivastigmine tartrate) for the treatment of mild to moderate dementia associated with Parkinson's disease. Parkinson's is a disorder of the central nervous system that causes chronic loss or impairment of intellectual capacity....

HealthDay - TUESDAY, June 27 (HealthDay News) -- Seniors with no outward signs of dementia but some deterioration in memory could still harbor the accumulated brain plaques that are typical of Alzheimer's disease, a new study suggests.

AP - A drug already sold to treat mild to moderate dementia in Alzheimer's disease patients won federal approval Tuesday to treat the same condition in Parkinson's patients.

HealthDay - TUESDAY, June 27 (HealthDay News) -- Seniors with no outward signs of dementia but some deterioration in memory could still harbor the accumulated brain plaques that are typical of Alzheimer's disease, a new study suggests.

Reuters - Poor physical performance is associated with an increased risk of dementia and Alzheimer's disease among individuals 65 years of age or older, according to a new report. The findings suggest that diminished physical function precedes the onset of cognitive impairment.

Poor physical function could indicate an increased risk of Alzheimer’s disease and other dementias, according to a new study. "Even the mildest degree if physical disability is going to predict a heightened risk of Alzheimer’s," says...

HealthDay - MONDAY, May 22 (HealthDay News) -- Poor physical function may be a warning sign of increased risk of Alzheimer's disease and other dementias, a new study suggests.

HealthDay - MONDAY, May 22 (HealthDay News) -- Poor physical function may be a warning sign of increased risk of Alzheimer's disease and other dementias, a new study suggests.

Reuters - Novartis Pharmaceuticals' drug Exelon is safe for treating dementia in patients with Parkinson's disease, a U.S. advisory panel recommended on Wednesday.

Reuters - Novartis Pharmaceuticals' drug Exelon is safe for treating dementia in patients with Parkinson's disease, a U.S. advisory panel recommended on Wednesday.